Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: Case report and review of infectious complications associated with tumor necrosis factor α inhibitor use

Diagnostic Microbiology and Infectious Disease

Volumn 53, Issue 3, 2005, Pages 233-238

  Mufti, Areej H ^a   Toye, Baldwin W ^a,b   Mckendry, Robert R J ^b   Angel, Jonathan B ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Etanercept; Infliximab; Mycobacterium; TNF

Indexed keywords

CLARITHROMYCIN; INFLIXIMAB;

AGED; BACTERIAL GROWTH; CASE REPORT; FEMALE; HUMAN; MEDICAL LITERATURE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 27744603956     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.06.006     Document Type: Article

References (68)

1. A. Alldred Etanercept in rheumatoid arthritis Expert. Opin. Pharmacother. 2 2001 1137 1148
2. A.G. Aparicio, S. Munoz-Fernandez, G. Bonilla, A. Miralles, V. Cerdeno, and E. Martin-Mola Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Gluck et al Arthritis Rheum. 48 2003 1764 1766
3. S.M. Arend, F.C. Breedveld, and J.T. van Dissel TNF-alpha blockade and tuberculosis: better look before you leap Neth. J. Med. 61 2003 111 119
4. M. Baghai, D.R. Osmon, D.M. Wolk, L.E. Wold, G.J. Haidukewych, and E.L. Matteson Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept Mayo Clin. Proc. 76 2001 653 656
5. A. Belda, J. Hinojosa, B. Serra, L. Garcia, C. Merino, and J.R. Moles Systemic candidiasis and infliximab therapy Gastroenterol. Hepatol. 27 2004 365 367
6. J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, E. Grommica-Ihle, H. Kellner, A. Krause, M. Schneider, H. Sorensen, H. Zeilder, W. Thriene, and J. Sieper Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial Lancet 359 2002 1187 1193
7. B. Bresnihan, and G. Cunnane Infection complications associated with the use of biologic agents Rheum. Dis. Clin. North Am. 29 2003 185 202
8. A.P. Cairns, and A.J. Taggart Anti-tumor necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland Ulster Med. J. 71 2002 101 105
9. A.T. Chan, V. Cleeve, and T.J. Daymond Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis Postgrad. Med. J. 78 2002 47 48
10. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N. Engl. J. Med. 344 2001 907 916
11. G. Cunnane, M. Doran, and B. Bresnihan Infections and biological therapy in rheumatoid arthritis Best Pract. Res. Clin. Rheumatol. 17 2003 345 363
12. A.M. Dannenburg Jr. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis Immunol. Today 12 1991 228 233
13. C.T. Derk, and R.J. DeHoratius Tuberculous tonsillitis in a patient receiving etanercept treatment Ann. Rheum. Dis. 62 2003 372
14. F.G. De Rosa, D. Shaz, A.C. Campagna, P.E. Dellaripa, U. Khettry, and D. Craven Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: possible health care associated case? Infect. Control Hosp. Epidemiol. 24 7 2003 477 482
15. S. Ehlers, J. Benini, S. Kutsch, R. Endres, E.T. Rietschel, and K. Pfeffer Fatal granuloma necrosis without exacerbated mycobacterial growth in tumour necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium Infect. Immun. 67 1999 3571 3579
16. R.L. Elwood, M.M. Pleszynski, and L.I. Corman Multifocal septic arthritis and osteomylitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept Pediatr. Infect. Dis. J. 22 2003 286 288
17. S.L. Erickson, F.J. deSauvage, K. Kikly, K. Carver-Moore, S. Pitts-Meek, N. Gillett, K.C. Sheehan, R.D. Schreiber, D.V. Goeddel, and M.W. Moore Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice Nature 372 1994 560 563
18. J.L. Flynn, M.M. Goldstein, J. Chan, K.J. Triebold, K. Pfeffer, C.J. Lowenstein, R. Schreiber, T.W. Mak, and B.R. Bloom Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice Immunity 2 1995 561 572
19. A. Fu, J.V. Bertouch, and H.P. McNeil Disseminated Salmonella typhimurium infection secondary to infliximab treatment Arthritis Rheum. 50 2004 3049
20. M. Gardam, E. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect. Dis. 3 2003 148 155
21. E. Giacomini, E. Iona, L. Ferroni, M. Miettinen, L. Fattorini, G. Orefici, I. Julkunen, and E.M. Coccia Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response J. Immunol. 166 2001 7033 7041
22. G.S. Gottlieb, C.F. Lesser, K.K. Holmes, and A. Wald Disseminated sporotrichosis associated with treatment with immunosuppresants and tumor necrosis factor-alpha antagonists Clin. Infect. Dis. 37 2003 838 841
23. C. Greene, G. Lowe, C. Taggart, P. Gallagher, McElvaney, and S. O'Neil Tumour necrosis factor-alpha-converting enzyme: its role in community-acquired pneumonia J. Infect. Dis. 186 2002 1790 1796
24. S. Harney, F.D. O'Shea, and O. FitzGerald Peptostreptococcal pericarditis complicating anti-tumor necrosis factor alpha treatment in rheumatoid arthritis Ann. Rheum. Dis. 61 2002 653 654
25. D. Helbling, T.H. Breitbach, and M. Krause Disseminated Cytomegalovirus infection in Crohn's disease following antitumour necrosis factor therapy Eur. J. Gastroenterol. Hepatol. 14 2002 1393 1395
26. K.R. Herrlinger, A. Borutta, G. Meinhardt, E.F. Stange, and K. Fellerman Fatal staphylococcal sepsis in Crohn's disease after infliximab Inflamm. Bowel Dis. 10 2004 655 656
27. H. Hsu, J. Xiong, and D.V. Goeddel The TNF receptor I-associated protein TRADD signals cell death and NF-kappa B activation Cell 81 1995 495 504
28. J. Jansen, T. Van der Poll, M. Levi, H. ten Cate, H. Gallati, J.W. ten Cate, and S.J. van Deventer Inhibition of the release of soluble tumour necrosis factor receptors in experimental endotoximia by an anti-tumour necrosis factor-alpha antibody J. Clin. Immunol. 15 1995 45 50
29. N. Juffermans, A. Verbon, S. Deventer, H. Deutekom, P. Speelman, and P. Poll Tumor necrosis factor and interleukin-1 inhibitors as markers of disease activity of tuberculosis Am. J. Respir. Crit. Care Med. 157 1998 1328 1331
30. B.M. Kamath, P. Mamula, R.N. Baldassano, and J.E. Markowitz Listeria meningitis after treatment with infliximab J. Pediatr. Gastroenterol. Nutr. 34 2002 410 412
31. J. Keane, S. Gershon, R. Wise, E. Merabile-Levens, J. Kasznica, W. Schwieterman, J. Siegel, and M. Miles Braun Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent N. Engl. J. Med. 345 2001 1098 1104
32. A. Kirchgatterer, T. Weber, M. Hinterreiter, P. Knoflach, and F. Allerberger Haemorrhagic colitis due to Escherichia coli O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis Rheumatology (Oxford) 41 2002 355 356
33. K. Kisich, M. Higgins, G. Diamond, and L. Heifets Tumour necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils Infect. Immun. 70 2002 4591 4599
34. D.M. Knight, C. Wagner, R. Jordan, M.F. McAleer, R. DeRita, D.N. Fass, B.S. Coller, H.F. Weisman, and J. Ghrayeb The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions Mol. Immunol. 32 1995 1271 1281
35. S. Kroesen, A.F. Widmer, A. Tyndall, and P. Hasler Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy Rheumatology (Oxford) 42 2003 617 621
36. J.H. Lee, N.R. Slifman, S.K. Gershon, E.T. Edwards, W.D. Schwieterman, J.N. Sieg, R.P. Wise, S.L. Brown, J.N. Udall Jr., and M.M. Braun Life threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept Arthritis Rheum. 461 2002 2565 2570
37. F. Mackay, H. Loetscher, D. Stueber, G. Gehr, and W. Lesslauer Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55 J. Exp. Med. 177 1993 1277 1286
38. R. Maini, E.W. St Clair, F. Breedveld, D. Frust, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group Lancet 354 1999 1932 1939
39. D.A. McNamara, D. Molony, J. Mulsow, and P.R. O'Connell Biliary sepsis in a patient on anti-TNF alpha therapy Ir. J. Med. Sci. 170 2001 210 211
40. B. Modzelewski Soluble TNF p55 and p75 receptors in development of sepsis syndrome Pol. Merkuriusz Lek. 14 2003 69 72
41. V.P. Mohan, C.A. Scanga, K. Yu, H.M. Scott, K.E. Tanaka, E. Tsang, M.M. Tsai, J.L. Flynn, and J. Chan Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology Infect. Immun. 69 2001 1847 1855
42. A.K. Mohan, T.R. Cote, J.N. Siegel, and M.M. Braun Infectious complications of biologic treatments of rheumatoid arthritis Curr. Opin. Rheumatol. 15 2003 179 184
43. M. Nakelchik, and J.E. Mangino Reactivation of histoplasmosis after treatment with infliximab Am. J. Med. 112 2002 78
44. M.G. Netea, T. Radstake, L.A. Joosten, J.W. Van der Meer, P. Barrere, and B.J. Kullberg Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression Arthritis Rheum. 48 2003 1853 1857
45. K.A. Papadakis, and S.R. Targan Tumor necrosis factor: biology and therapeutic implications Gastroenterology 119 2000 1148 1157
46. S. Patel, A. Kulkarni, R. Agrawal, and A. Shawali Cutaneous tuberculosis associated with infliximab treatment Am. J. Gastroenterol. 98 2003 S185 S186
47. L. Peno-Green, G. Lluberas, T. Kingsley, and S. Brantley Lung injury linked to etanercept therapy Chest 122 2002 1858 1860
48. K. Philips, M.E. Husni, E.W. Karlson, and J.S. Coblyn Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum. 47 2002 17 21
49. A.M. Reimold New indications for treatment of chronic inflammation by TNF-alpha blockade Am. J. Med. Sci. 325 2003 75 92
50. M.A. Ritz, and R. Jost Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease Inflamm. Bowel Dis. 7 2001 327
51. J. Rothe, F. Mackay, H. Bluethmann, R. Zinkernagel, and W. Lesslauer Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-defiecent fibroblasts in vitro Circ. Shock 44 1994 51 56
52. J.P. Ruiz, N.O. Centeno, and E.R. Alvarez Development of tuberculosis in patients treated with infliximab who had received prophylactic therapy with isoniazid J. Rheumatol. 30 2003 1657 1658
53. B.M. Saunders, H. Briscoe, and W.J. Britton T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection Clin. Exp. Immunol. 137 2004 279 287
54. B.M. Saunders, S. Tran, S. Ruuls, J.D. Sedgwick, H. Briscoe, and W.J. Britton Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection J. Immunol. 174 2005 4852 4859
55. B.J. Scallon, M.A. Moore, H. Trinh, D.M. Knight, and J. Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions (1995) Cytokine 7 1995 251 259
56. M. Seddik, H. Meleiz, D. Seguy, N. Viget, A. Cortot, and J.F. Colombel Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease Inflamm. Bowel Dis. 10 2004 436 437
57. S.M. Singh, N.V. Rau, L.B. Cohn, and H. Harris Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone CMAJ 171 2004 1063 1064
58. N.R. Slifman, S.K. Gershon, J.H. Lee, E.T. Edwards, and M.M. Braun Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents Arthritis Rheum. 48 2003 319 324
59. D. Smith, and S. Letendre Viral pneumonia as a serious complication of etanercept therapy Ann. Intern. Med. 136 2002 174
60. T.L. Tai, K.P. O'Rourke, M. Mcweeney, C.M. Burke, K. Sheehan, and M. Barry Pneumocystis carinii pneumonia following a second infusion of infliximab Rheumatology (Oxford) 41 2002 951 952
61. J.C. Taylor, R. Orkin, and J. Lanham Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy Rheumatology (Oxford) 42 2003 901 902
62. S.J. van Deventer Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease Gastroenterology 121 2001 1242 1246
63. F.S. Velayos, and W.J. Sandborn Pneumocystis carinii pneumonia during maintenance anti-tumour necrosis factor-alpha therapy with infliximab for Crohn's disease Inflamm. Bowel Dis. 10 2004 657 660
64. R.S. Wallis, M.S. Broder, J. Wong, D.O. Beenhouwer, and M.E. Hanson Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin. Infect. Dis. 38 2004 1261 1265
65. R.S. Wallis, M.S. Broder, J.Y. Wong, and D. Beenhouwer Granulomatous infections due to tumor necrosis factor blockade: correction Clin. Infect. Dis. 39 2004 1254 1255
66. M.J. Wondergem, A.E. Voskuyl, and M.A. Van agtmael A case of legionellosis during treatment with a TNF alpha antagonist Scand. J. Infect. Dis. 36 2004 310 311
67. K.L. Wood, C.A. Hage, K.S. Knox, M.B. Kleiman, A. Sannuti, R.B. Day, L.J. Whea, and H.L. Twigg Histoplasmosis after treatment with anti-tumor necrosis factor alpha therapy Am. J. Respir. Crit. Care Med. 167 2003 1279 1282
68. Y.X. Zhao, H. Zhang, B. Chiu, U. Payne, and R.D. Inman Tumour necrosis factor receptor p55 controls the severity of arthritis in experimental Yersinia enterocolitica infection Arthritis Rheum. 42 1999 1662 1672